Pegasys Pegintron Ribavirin

Description

Pegasys (peginterferon alfa-2a), Pegintron (peginterferon alfa-2b), Ribavirin (Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules)

Background

Hepatitis C is a viral disease caused by the hepatitis C virus (HCV) that leads to inflammation of the liver. Most people who were recently infected with hepatitis C do not have symptoms, but most people infected with hepatitis C develop a chronic infection. Untreated, chronic infection can lead to liver cirrhosis and/or liver cancer. Six genotypes of the hepatitis C virus exist and genotyping is essential to effective treatment. Hepatitis C infection may be detected in the blood by the HCV RNA assay. Disease status may be monitored by assays of biochemical liver tests or liver biopsy (1).

The goals of HCV treatment are to remove the virus from the blood and reduce the risk of cirrhosis and liver cancer that can result from long-term HCV infection. The most common treatment regimens are based on combinations of pegylated interferon alfa, ribavirin, and a protease inhibitor (1).

Chronic hepatitis B virus (HBV) infection is a growing health problem affecting over a million people in the United States and at least 350 million people worldwide (2). Patients with chronic hepatitis B are at an increased risk to develop cirrhosis, liver failure, and liver cancer. The goal of chronic hepatitis B therapy is to prevent these complications by decreasing the patient’s hepatitis B viral level and maintaining it at low levels for as long as possible (3).
Hepatitis B e antigen (HBeAg) and Hepatitis B viral DNA (HBV DNA) are both markers of HBV replication and their presence provides a rationale for initiating therapy to stop the progression of liver disease. In the past, the ability to detect HBV DNA in the serum by hybridization assays was a major factor in determining which patients should be treated. This assay is sensitive enough to detect viral DNA when it is present in amounts $\geq 10^5$ copies/ml and consequently this viral level became an important benchmark in treatment algorithms. As improvements in viral detection have advanced it has become apparent that it is not possible to designate a single HBV DNA value that can differentiate between inactive hepatitis B carriers and patients suffering from chronic hepatitis B. Recent practice guidelines have recommended that alanine aminotransferase (ALT) levels and liver biopsies can be used to determine which patients with low HBV DNA levels require treatment (3).

Pegasys works by both stimulating the immune system and inhibiting viral replication. It also has a longer half-life than conventional interferon which allows for once-weekly dosing (5). Pegasys has been shown to produce superior clinical outcomes in patients with HBeAg-positive chronic HBV and significantly higher response rates in chronic HBV patients that are HBeAg-negative (4).

For patients with compensated cirrhosis the goal is to prevent the progression to decompensated cirrhosis and to prevent the development of liver cancer. Interferon therapy is not recommended in patients with decompensated cirrhosis because it increases their risk for developing bacterial infections and it can potentially worsen their condition (5).

**Regulatory Status**

FDA-approved indications: (6-10)

1. Pegasys is an antiviral indicated for the treatment of chronic hepatitis C (CHC) in patients 5 years of age and older with compensated liver disease
2. Pegasys monotherapy is indicated for CHC only if patient has contraindication to or significant intolerance to other HCV antiviral drugs
3. Pegasys monotherapy is also indicated for treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation
4. PegIntron, as part of a combination regimen, is an antiviral indicated for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease
5. PegIntron monotherapy should only be used in the treatment of CHC in patients with compensated liver disease if there are contraindications to or significant intolerance of ribavirin and is indicated for use only in previously untreated adult patients
## Limitations of Use:

Pegasys alone or in combination with ribavirin without additional HCV antiviral drugs is not recommended for treatment of patients with CHC who previously failed therapy with an interferon-alfa. Pegasys is not recommended for treatment of patients with CHC who have had solid organ transplantation (6).

If Pegasys is administered with other antiviral agents, the contraindications to those agents also apply to the combination regimen (6).

PegIntron may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or worsening signs or symptoms of the above disorders (7).

Ribavirin may cause birth defects and fetal death: avoid pregnancy in female patients and female partners of male patients (8-10).

### Related policies

**Intron A**

<table>
<thead>
<tr>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.</em></td>
</tr>
</tbody>
</table>

Pegasys with or without ribavirin may be considered **medically necessary** for the treatment of chronic hepatitis C or hepatitis B and if the conditions indicated below are met.

PegIntron with or without ribavirin may be considered **medically necessary** for the treatment of chronic hepatitis C and if the conditions indicated below are met.

Pegasys with or without ribavirin is considered **investigational** for all other indications.

PegIntron monotherapy is considered **investigational** for patients less than 18 years of age and for all other indications.

### Prior-Approval Requirements
Pegasys or Pegintron alone for Hepatitis C

Age  
5 years of age or older for Pegasys
18 years of age or older for Pegintron

Diagnosis

Patient must have the following:
1. Chronic hepatitis C

AND ALL of the following:
   a. Detectable viral load in the serum
   b. Compensated liver disease
   c. NOT previously treated with interferon alpha
   d. Significant intolerance or contraindication to ribavirin or other antiviral agents
   e. **Pegintron only:** A viral load will be drawn at treatment week 24

Pegasys with ribavirin or Pegintron with ribavirin

Age  
5 years of age or older for Pegasys with ribavirin
3 years of age or older for Pegintron with ribavirin

Diagnosis

Patient must have the following:
1. Chronic hepatitis C

AND ALL of the following:
   a. Detectable viral load in the serum
   b. Compensated liver disease
   c. Viral genotype must be provided and if genotype 1 must NOT be an appropriate candidate for treatment with a protease inhibitor
   d. **Pegasys with ribavirin only:** NOT diagnosed with renal failure if age 5 to 17
   e. **Pegintron with ribavirin only:** NOT diagnosed with renal failure if age 3 to 17
   f. Neither the patient nor the partner of the patient is pregnant
   g. Will be instructed to practice effective contraception during therapy and
for 6 months after stopping ribavirin therapy if either the patient or their partner are of child bearing age

h. Viral load will be drawn at treatment week 24 if not coinfected with HIV

**Pegasys for Hepatitis B**

**Age** 3 years of age or older

**Diagnosis**

Patient must have the following:

1. Chronic hepatitis B

**AND ALL** of the following:

a. Compensated liver disease

b. Evidence of viral replication

**Prior – Approval Renewal Requirements**

**Pegintron alone**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

Hepatitis C

**AND** the following:

a. An UNDETECTABLE viral load after the initial 24 weeks of therapy

**Pegasys with ribavirin or Pegintron with ribavirin**

**Age** 5 years of age or older for Pegasys with ribavirin

3 years of age or older for Pegintron with ribavirin

**Diagnosis**
Patient must have ALL of the following:

1. **UNDETECTABLE** hepatitis C viral load after initial 24 weeks of therapy
2. Genotype 1, 4, 5 or 6
3. **Pegasys with ribavirin AND co-infected with HIV only: NOT** already treated for 12 months for Hepatitis C

**Pegasys with ribavirin only: OR ONE** of the following:

1. History of null or partial response to previous (non-protease inhibitor) treatment
2. Presence of cirrhosis

**Pegintron with ribavirin only: AND NONE** of the following:

1. HIV infection and already treated for 12 months
2. History of null or partial response to previous (non-protease inhibitor) treatment
3. Presence of cirrhosis

### Policy Guidelines

#### Pre - PA Allowance

None

#### Prior - Approval Limits

<table>
<thead>
<tr>
<th>Medication and Diagnosis</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegasys for Hepatitis C</td>
<td>12 months</td>
</tr>
<tr>
<td>Pegintron for Hepatitis C</td>
<td>7 months</td>
</tr>
<tr>
<td>Pegasys with ribavirin for Hepatitis C</td>
<td>7 months if not co-infected with HIV (all genotypes) 12 months if co-infected with HIV (all genotypes)</td>
</tr>
<tr>
<td>Pegintron with ribavirin for Hepatitis C</td>
<td>7 months if not co-infected with HIV (all genotypes) 12 months if co-infected with HIV (all genotypes)</td>
</tr>
<tr>
<td>Pegays for Hepatitis B</td>
<td>12 months</td>
</tr>
</tbody>
</table>
### Section: Prescription Drugs  
**Effective Date:** April 1, 2019  
**Subsection:** Anti-Infective Agents  
**Original Policy Date:** January 1, 2019  
**Subject:** Pegasys Pegintron Ribavirin  
**Page:** 7 of 8

<table>
<thead>
<tr>
<th>Medication and Diagnosis</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegasys for Hepatitis C</td>
<td>No renewal</td>
</tr>
<tr>
<td>Pegintron for Hepatitis C</td>
<td>5 months</td>
</tr>
</tbody>
</table>
| Pegasys with ribavirin for Hepatitis C  | 5 months (if age 5 to 17)  

*NO renewal for patients co-infected with HIV

<table>
<thead>
<tr>
<th></th>
<th>12 months (if age 18 or older)</th>
</tr>
</thead>
</table>
| Pegintron with ribavirin for Hepatitis C | 5 months (if age 3 to 17)  

<table>
<thead>
<tr>
<th>Pegays for Hepatitis C</th>
<th>12 months (if age 18 or older)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegays for Hepatitis B</td>
<td>No renewal</td>
</tr>
</tbody>
</table>

### Rationale

### Summary

Hepatitis C is a viral disease caused by the hepatitis C virus (HCV) that leads to inflammation of the liver. Untreated, chronic infection can lead to liver cirrhosis and/or liver cancer. The most common treatment regimens are based on combinations of pegylated interferon alfa, ribavirin, and a protease inhibitor (1).

Pegasys is an antiviral indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication (6).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Pegasys, Pegintron, and ribavirin while maintaining optimal therapeutic outcomes.

### References
5.01.47

<table>
<thead>
<tr>
<th>Section</th>
<th>Prescription Drugs</th>
<th>Effective Date:</th>
<th>April 1, 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsection:</td>
<td>Anti-Infective Agents</td>
<td>Original Policy Date:</td>
<td>January 1, 2019</td>
</tr>
<tr>
<td>Subject:</td>
<td>Pegasys Peginteron Ribavirin</td>
<td>Page:</td>
<td>8 of 8</td>
</tr>
</tbody>
</table>


**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 2018</td>
<td>Addition to PA</td>
</tr>
<tr>
<td></td>
<td>Merge of policy numbers 5.01.02, 5.01.07, 5.01.08, 5.01.11, 5.01.12</td>
</tr>
<tr>
<td>February 2019</td>
<td>Reworded renewal requirement for Pegasys with ribavirin, co-infected with HIV: not already treated for 12 months for Hepatitis C</td>
</tr>
<tr>
<td>March 2019</td>
<td>Annual review</td>
</tr>
</tbody>
</table>

**Keywords**

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 15, 2019 and is effective on April 1, 2019.